Skip to main content

Advertisement

SpringerLink
Log in

Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points

  • Letter to the Editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

A Correspondence to this article was published on 01 November 2022

The Original Article was published on 03 February 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable

Code availability

Not applicable

References

  1. Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y (2022) Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Support Care Cancer. https://doi.org/10.1007/s00520-022-06839-4. Online ahead of print

  2. Ng TL, Tu MM, Ibrahim MFK, Basulaiman B, McGee SF, Srikanthan A, Fernandes R, Vandermeer L, Stober C, Sienkiewicz M, Jeong A, Saunders D, Awan AA, Hutton B, Clemons MJ (2021) Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer 29(2):925–943. https://doi.org/10.1007/s00520-020-05556-0

    Article  PubMed  Google Scholar 

  3. Fasciolo A, Fusco V, De Martino I, Alessio M, Brigo T, Tartara D, Campora RA, Rossi M (2021) Prevention and screening of osteonecrosis of jaw (ONJ): the Alessandria experience of a multidisciplinary team on a 900-patient population. Qeios. https://doi.org/10.32388/0QK8E2

  4. Cabras M, Gambino A, Erovigni FM, Della Ferrera F, Freilone R, Pentenero M, Fasciolo A, Di Maio M, Ramieri G, Migliario M, Appendino P, Fusco V (2021) Osteonecrosis of the jaw (ONJ) in cancer and myeloma patients. A 16-year experience of “Rete Oncologica Piemonte – Valle d’Aosta” cancer network. Qeios. https://doi.org/10.32388/YIVAW8

  5. Cabras M, Gambino A, Conrotto D, Garrone M, Fasciolo A, Basano L, Gilardetti M, Galassi C, Fusco V (2021) Survival of metastatic cancer and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies. Qeios . https://doi.org/10.32388/IKLIWH

  6. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P (2012) Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 107(10):1665–1671. https://doi.org/10.1038/bjc.2012.385

    Article  CAS  PubMed Central  Google Scholar 

  7. van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26(3):869–878. https://doi.org/10.1007/s00520-017-3903-5

    Article  PubMed  Google Scholar 

  8. Fusco V, Campisi G, Bedogni A (2022) One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of Medication Related Osteonecrosis of the Jaw (MRONJ). Support Care Cancer. https://doi.org/10.1007/s00520-022-06982-y

    Article  PubMed Central  Google Scholar 

  9. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B (2017) Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update. J Clin Oncol 35(35):3978–3986. https://doi.org/10.1200/JCO.2017.75.4614

    Article  CAS  PubMed  Google Scholar 

  10. Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K, ESMO Guidelines Committee (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31(12):1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, Azienda Ospedaliera “SS Antonio E Biagio E C.Arrigo”, Via Venezia 16, 15121, Alessandria, Italy

    Vittorio Fusco & Maura Rossi

  2. DSS - Department of Surgical Sciences, Oral Medicine Section, University of Turin, CIR - Dental School, Turin, Italy

    Alessio Gambino

  3. Maxillofacial Surgery Unit, Azienda Ospedaliera “SS Antonio E Biagio E C.Arrigo”, Alessandria, Italy

    Antonella Fasciolo

  4. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS Istituto Giannina Gaslini, Genoa, Italy

    Serena Palmeri

Authors
  1. Vittorio Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maura Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonella Fasciolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessio Gambino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Serena Palmeri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the article. The first draft of the manuscript was written by Vittorio Fusco, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Vittorio Fusco.

Ethics declarations

Ethics approval

Not applicable

Consent to participate

Not applicable

Consent for publication

Not applicable

Conflict of interest

Vittorio Fusco received honoraria as a consultant by Merck; Maura Rossi received travel grants from AAA/Novartis; other authors declared no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fusco, V., Rossi, M., Fasciolo, A. et al. Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points. Support Care Cancer 30, 9707–9709 (2022). https://doi.org/10.1007/s00520-022-07214-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-022-07214-z

Search

Navigation